ONS Annual Congress Heralds Start of Oncology Nursing Month

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty.

PITTSBURGH—The Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty. The celebration kicks off on Thursday, May 4, 2006, on Oncology Nursing Day, during the Opening Ceremony of the Society's 31st Annual Congress in Boston, Massachusetts, and continues until May 31, 2006.

Oncology Nursing Month has been designed to recognize oncology nurses, to educate the public about oncology nursing, to provide an opportunity for special educational events for oncology nurses, and to celebrate the accomplishments of oncology nurses. A brochure with tips on how to promote Oncology Nursing Month is available on the Society's website at www.ons.org.

Look for comprehensive coverage of oral presentations, lectures, and posters from the Society's 31st Annual Congress in upcoming issues of ONI.

Articles in this issue
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLC
ONS Annual Congress Heralds Start of Oncology Nursing Month
All-Star Panel Spells Out Onc Promises, Problems
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosis
ODAC Says No to Gemzar for Ovarian Ca
Experts See Oncology Reimbursements Headed Down, Hard Negotiations With Payers Lie Ahead
Femara Effective Even After Years of No Therapy
XMRV Retrovirus Found in Some Prostate Ca's
Taxotere Wins FDA Approval for Advanced Gastric Cancer
Community Oncology Practices Struggle to Cope With the Extra Requirements of Medicare Part D
Director of NCI Nominated as New FDA Commissioner
TAM-01 Finds Longer Tamoxifen Duration Is Not Better
Erbitux Wins Approval for Squamous Cell H&N Cancer
Young Doctors Are Hungry for Psychological Oncology Training
Posaconazole Reduces Serious IFIs in High-Risk Patients
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.